Search Results

You are looking at 51 - 60 of 853 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Amitkumar Mehta, Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

involved in the B-cell receptor pathway have demonstrated promising activity for the treatment of relapsed/refractory FL. CAR T-cell therapy has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights

Full access

Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Shaji K. Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson Jr, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Christopher D’Angelo, Srinivas Devarakonda, Noura Elsedawy, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Hans C. Lee, Michaela Liedtke, Thomas Martin, James Omel, Timothy Robinson, Aaron Rosenberg, Douglas Sborov, Mark A. Schroeder, Daniel Sherbenou, Attaya Suvannasankha, Jason Valent, Asya Nina Varshavsky-Yanovsky, Rashmi Kumar, and Jenna Snedeker

Waldenström macroglobulinemia. This manuscript focuses only on management of relapsed/refractory MM. For the complete NCCN Guidelines for Multiple Myeloma, please visit nccn.org . Therapy for Previously Treated MM A variety of therapies are available

Full access

Maintenance Therapy With Tyrosine Kinase Inhibitors After Transplant in Patients With Chronic Myeloid Leukemia

Merav Bar and Jerald Radich

Therefore, which patients with CML should be considered for allogeneic transplant? Not many. With imatinib, approximately 40% of patients will eventually discontinue therapy, either because of initial failure to achieve milestones, intolerance, or relapse

Full access

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Babis Andreadis, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Julie E. Chang, Beth Christian, Sven DeVos, Bhagirathbhai Dholaria, Luis E. Fayad, Thomas M. Habermann, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Boyu Hu, Mark S. Kaminski, Yasmin Karimi, Christopher R. Kelsey, Rebecca King, Susan Krivacic, Ann S. LaCasce, Megan Lim, Marcus Messmer, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

MCL with TP53 mutation, and aids in the selection of appropriate treatment, particularly if up-front HDT/ASCR is anticipated. 10 These NCCN Guidelines Insights discuss recent updates to the management of newly diagnosed and relapsed

Full access

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016

Steven M. Horwitz, Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar, and Pierluigi Porcu

Second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant (SCT), based on the patient's eligibility for transplant, is the standard treatment approach for patients with relapsed or refractory disease. The management of patients

Full access

Updates in Treatment Strategies for Hodgkin Lymphoma

Ranjana H. Advani

Given the myriad of treatment options available for frontline treatment of advanced-stage Hodgkin lymphoma (HL) and for relapsed HL, clinicians must evaluate the advantages and disadvantages of each regimen, balancing risk with benefit for the

Full access

Management of Patients With Advanced Melanoma

Presented by: Genevieve Boland

, hazard ratio; Ipi, ipilimumab; Nivo, nivolumab; NR, not reached; Pembro, pembrolizumab; RFS, relapse-free survival. In 2014, the CTLA-4 inhibitor ipilimumab became the first approved immunotherapy for the adjuvant treatment of melanoma, but its

Full access

Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond

Jae Park

cell transplant (HSCT). At the NCCN 2019 Annual Congress: Hematologic Malignancies, Jae Park, MD, Associate Attending Physician, Memorial Sloan Kettering Cancer Center, summarized key studies of novel immunotherapies in relapsed/refractory (R/R) ALL and

Full access

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Robert Chen, Bouthaina Dabaja, Robert Dean, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Kami Maddocks, David G. Maloney, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Rachel Rabinovitch, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Ndiya Ogba

the reduction of long-term toxicity. However, 10% to 20% 3 – 6 of patients with favorable features and early-stage disease and up to 30% 7 , 8 with advanced-stage disease experience relapse. The standard treatment option for chemosensitive patients

Full access

Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by: Jennifer R. Brown

—typically obinutuzumab in the frontline setting and rituximab in the relapsed setting,” Dr. Brown noted at the NCCN 2021 Virtual Congress: Hematologic Malignancies. “But we still, nonetheless, have many unanswered questions.” According to Dr. Brown, current efforts in